Business Description
Mirum Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US6047491013
Total Employee Number:
418Compare
Compare
Traded in other countries / regions
MIRM.USA08D.GermanyMIRM.Mexico Index Membership
Russell 2000Russell 3000 IPO Date
2019-07-18Description
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.57 | |||||
Equity-to-Asset | -0.01 | |||||
Debt-to-Equity | -73.21 | |||||
Debt-to-EBITDA | -0.93 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.23 | |||||
Beneish M-Score | -1.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 66.1 | |||||
3-Year EPS without NRI Growth Rate | 51.2 | |||||
3-Year Book Growth Rate | 16.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 25.55 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.23 | |||||
9-Day RSI | 42.46 | |||||
14-Day RSI | 41.7 | |||||
3-1 Month Momentum % | 14.29 | |||||
6-1 Month Momentum % | 22.61 | |||||
12-1 Month Momentum % | 52.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.86 | |||||
Quick Ratio | 2.74 | |||||
Cash Ratio | 1.97 | |||||
Days Inventory | 79.58 | |||||
Days Sales Outstanding | 72.73 | |||||
Days Payable | 79.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12 | |||||
Shareholder Yield % | -6.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.73 | |||||
Operating Margin % | -14.76 | |||||
Net Margin % | -139.18 | |||||
EBITDA Margin % | -132.37 | |||||
FCF Margin % | -42.67 | |||||
OCF Margin % | -36.77 | |||||
ROE % | -393.16 | |||||
ROA % | -100.27 | |||||
ROIC % | -25.47 | |||||
3-Year ROIIC % | 63.22 | |||||
ROC (Joel Greenblatt) % | -6397.8 | |||||
ROCE % | -128.55 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1816.4 | |||||
PS Ratio | 9.19 | |||||
EV-to-EBIT | -7.5 | |||||
EV-to-EBITDA | -7.74 | |||||
EV-to-Revenue | 10.25 | |||||
EV-to-Forward-Revenue | 9.02 | |||||
EV-to-FCF | -24.01 | |||||
Price-to-GF-Value | 1.2 | |||||
Earnings Yield (Greenblatt) % | -13.33 | |||||
FCF Yield % | -4.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MIRM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mirum Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 618.067 | ||
| EPS (TTM) ($) | -14.55 | ||
| Beta | 0.9708 | ||
| 3-Year Sharpe Ratio | 1.1 | ||
| 3-Year Sortino Ratio | 2.9 | ||
| Volatility % | 54.52 | ||
| 14-Day RSI | 41.7 | ||
| 14-Day ATR ($) | 4.360307 | ||
| 20-Day SMA ($) | 100.64825 | ||
| 12-1 Month Momentum % | 52.33 | ||
| 52-Week Range ($) | 63.232 - 130 | ||
| Shares Outstanding (Mil) | 60.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mirum Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mirum Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 16:30 | In 183 days | ||
| Annual report for 2026 | 2027-02-25 | In 182 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 182 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 70 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 69 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 104.33 (-0.71%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 104.33 (-0.71%) | ||
| Guidance call for 2026 | 2026-05-20 13:35 | 95.65 (+0.61%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 15:30 | 95.49 (-6.56%) | ||
| General meeting for 2026 | 2026-05-15 09:00 | 111.39 (+2.04%) |
Show
Entries
Mirum Pharmaceuticals Inc Frequently Asked Questions
What is Mirum Pharmaceuticals Inc(MIRM)'s stock price today?
The current price of MIRM is $98.52. The 52 week high of MIRM is $130.00 and 52 week low is $63.23.
When is next earnings date of Mirum Pharmaceuticals Inc(MIRM)?
The next earnings date of Mirum Pharmaceuticals Inc(MIRM) is 2026-11-04 Est..
Does Mirum Pharmaceuticals Inc(MIRM) pay dividends? If so, how much?
Mirum Pharmaceuticals Inc(MIRM) does not pay dividend.
Guru Commentaries on NAS:MIRM
2025 Q3
What the manager wrote
Mirum Pharmaceuticals has been highlighted as a contributor to positive relative performance in the biotech sector, which gained approximately 22% due to positive trial results and improving investor sentiment. The company delivered on positive data and commercial catalysts, indicating strong growth potential. This performance aligns with our strategy of investing in companies with idiosyncratic growth and profitability levers, positioning us well for future market outcomes.
2025 Q2
What the manager wrote
Mirum Pharmaceuticals has demonstrated strong commercial sales execution, contributing positively to our portfolio's performance. The company is benefiting from favorable market conditions and has shown idiosyncratic growth drivers that align with our investment strategy. We believe that the ongoing execution of their business model positions them well for future growth, especially as we see robust demand in the biotech sector.
Press Release
Articles on Mirum Pharmaceuticals Inc
Headlines
See More- 1
Aug 20, 2026
ProQR a new buy at BoA on RNA-editing platform
Seeking Alpha • 8:49am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers